Led by founder David Elmaleh, Ph.D., a renowned and prolific inventor and molecular scientist, the AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably. The company’s license agreements and close relationships with three separate laboratories at Harvard University and Massachusetts General Hospital (MGH):
have enabled a strong patent portfolio, collaborative research, and access to some of the leading pioneers in neuroscience.
Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease is now fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative diseases.
AZTherapies is a private company headquartered in Boston, Massachusetts.